Cumberland Pharmaceuticals to Submit Ifetroban NDA for DMD Cardiomyopathy
Cumberland Pharmaceuticals says it plans to submit an NDA to the FDA for ifetroban as a treatment for DMD cardiomyopathy.
Story updates
08:43:36 PM UTC
SquawkNews
Cumberland Pharmaceuticals plans to seek FDA approval of ifetroban for Duchenne muscular dystrophy-related cardiomyopathy, using Phase 2 and natural-history data.Key Highlights:Original SEC Filing: CUMBERLAND PHARMACEUTICALS INC [ CPIX ] - 8-K - Oct. 26, 2026This is an AI-powered summary. It may co…